Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEMP1972A · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| MEMP1972A 150 mg | EXPERIMENTAL | - |
| MEMP1972A 300 mg | EXPERIMENTAL | - |
| MEMP1972A 450 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MEMP1972A | DRUG | Subcutaneous repeating dose |
| placebo | DRUG | Subcutaneous repeating dose |
Inclusion Criteria: * Adult patients, 18 to 75 years of age inclusive * Body weight \>/= 40 kg * Physician's diagnosis of asthma for at least 12 months * Evidence of documented bronchodilator reversibility as defined by protocol * Prebronchodilator FEV1 \>/= 40% and \</= 80% predicted at Visit 1 * ...
MEMP1972A is an investigational small molecule being developed by Roche Holding AG for the treatment of allergic rhinitis and asthma. It has been studied in clinical trials for these respiratory conditions, including in patients with allergic asthma inadequately controlled on inhaled steroids and a second controller.
MEMP1972A is a small molecule, but its specific molecular target has not been disclosed in the available information. The drug has been investigated for its effects on allergic rhinitis and asthma, suggesting it may modulate pathways involved in allergic airway inflammation.
MEMP1972A is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company has sponsored clinical trials of this investigational drug for allergic rhinitis and asthma.
MEMP1972A has completed Phase 1 and Phase 2 clinical trials. The most advanced studies were Phase 2 trials in asthma patients. However, the drug is still investigational and has not been approved by regulatory authorities.
MEMP1972A has been studied in three completed trials: NCT01160861, a Phase 1 safety and pharmacokinetics study in allergic rhinitis patients; NCT01196039 (SOLARIO), a Phase 2 study in mild asthma; and NCT01582503 (COSTA), a Phase 2 study in allergic asthma patients on inhaled steroids and a second controller.
MEMP1972A is not known to have alternative names. It is a distinct investigational compound developed by Roche, and no other names for this drug have been reported in the available clinical trial information.